Abstract
Julia McKenna, Rachelle Payandeh, Yelena Aizenberg, Melica Nourmoussavi Brodeur, Mark Stafford Carey, Sarah E. Ferguson, Laura Hopkins, Iwa Kong, Janice S. Kwon, Susie K. Lau, Donna Pepin, Karla Willows, Christa Wood, Helen M. McTaggart-Cowan
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints
10.3390/ijms20040952 · 2019
PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance
10.3389/fcell.2020.564601 · 2020
Homologous recombination deficiency: concepts, definitions, and assays
10.1093/oncolo/oyab053 · 2022
Prevalence of homologous recombination deficiency in first-line PARP inhibitor maintenance clinical trials and further implication of personalized treatment in ovarian cancer
10.3390/cancers15123095 · 2023
BRCA mutation in high grade epithelial ovarian cancers
10.1016/j.gore.2019.07.007 · 2019
Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer
10.1056/nejmoa1810858 · 2018
The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities
10.1016/j.ygyno.2018.01.011 · 2018
Unresolved referenced work
Kept as external metadata until matched
Shared decision-making as a method of care
10.1136/bmjebm-2022-112068 · 2023
Recombination deficiency testing to inform patient decisions about Niraparib maintenance therapy for high-grade serous or endometrioid epithelial ovarian cancer: a health technology assessment
2023
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Applying the health belief model to explore healthcare provider and patient perspectives on homologous recombination deficiency testing in cancer: a narrative review
2026
Unresolved referenced work
Kept as external metadata until matched
10.1093/intqhc/mzm042
10.1093/intqhc/mzm042
10.1177/02692163241234800
10.1177/02692163241234800
How do you solve a problem like COREQ? A critique of Tong et al.’s (2007) consolidated criteria for reporting qualitative research
10.1016/j.metip.2024.100155 · 2024
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support
10.1016/j.jbi.2008.08.010 · 2009
Qualitative research: standards, challenges, and guidelines
10.1016/s0140-6736(01)05627-6 · 2001
Unresolved referenced work
Kept as external metadata until matched
Reflecting on reflexive thematic analysis
10.1080/2159676x.2019.1628806 · 2019
Using thematic analysis in psychology
10.1191/1478088706qp063oa · 2006
Refining PARP inhibitor use in HGSOC: The role of HRD testing in clinical decision making
10.1016/j.ygyno.2026.01.215 · 2026
Implementing HRD testing in routine clinical practice on patients with primary high-grade advanced ovarian cancer
10.3390/cancers15030818 · 2023
Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success
10.1080/14796694.2024.2433412 · 2025
Understanding communication between patients and healthcare professionals regarding comprehensive biomarker testing in precision oncology: a scoping review
10.1002/cam4.6913 · 2024
Exploring cancer patients’ and caregivers’ perspectives and knowledge regarding biomarker testing in Canada
10.3390/curroncol32060292 · 2025
Unresolved referenced work
Kept as external metadata until matched
I think that a brief conversation from their provider can go a very long way”: patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer
2021
What you’re hearing from all of us is simplify the language”: patient perspectives on biomarker testing in ovarian cancer
10.1016/j.ygyno.2025.08.009 · 2025
The Development and testing of a patient decision aid for individuals with homologous recombinant proficient ovarian cancer who are considering Niraparib maintenance therapy
10.3390/curroncol31030107 · 2024
10.1016/j.ygyno.2024.07.585
10.1016/j.ygyno.2024.07.585
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: a qualitative study
10.1016/j.ygyno.2020.10.034 · 2021
A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer
10.1016/j.ygyno.2017.05.039 · 2017
Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment
10.1016/j.ygyno.2020.01.026 · 2020
Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: findings from two online community events
2022
Reinforcing the humanity in healthcare: the Glasgow Consensus Statement on effective communication in clinical encounters
10.1016/j.pec.2024.108158 · 2024
No additional external references are available.